Shinpoong to activate anti-malaria drug development.

Published: 2002-10-25 06:56:00

Updated: 2002-10-25 06:56:00

Shinpoong signed an agreement with WHO-MMV at Marriot hotel in Seoul on Oct. 15 for a joint development of Pyronaridine artesunate, an anti-malaria drug. When successfully developed, WHO-MMV will be responsible for the world product registration whereas Shinpoong supplies the product.

Shinpo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK